ZTS Zoetis Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 2-year channel falling
Price is between the lines.
- 2-year channel
- US$67.83 – US$101.44 · falling, −34% a year
- Price in channel
- 46% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$101.44
- Turns bearish below
- US$67.83
Price history, with the path projected 3 months forward
Updated 3:59 PM ET (7 h ago)
- Daily close
- Upper trend line (2 years)
- Lower trend line (2 years)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
Hit rate too low on this symbol (3/8) — no published call or alerts; levels below are for reference.
Buy at or below
US$73.29
level as at 17 Nov 2026
Our target
US$82.09
by 4 Nov 2026
Projected move
12.0%
gross, before costs
Price is at or past our target.
Target: ZTS's usual move size (12.0%), the best return per day on this path.
8 settled calls · 3 reached target (37.5%) · average best move 6.6%. See the full record.
- Upper line touches
- 8
- Lower line touches
- 4
- Fit confidence
- 52%
- Fitted
- 2 Nov 2026
Company information
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kristin C. Peck
- Employees
- 14,500
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$32.78B
- Enterprise value
- —
- Beta
- 0.74
- Avg volume
- 5.76M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 68.77-148.3
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.